Cerenome, Inc. (NasdaqCM: CNSY)
Health Care · Biotechnology · US
$1.64
-6.29% today · -89.7% 1Y
Cerenome, Inc. (NasdaqCM: CNSY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.45M and employs 28 people.
Over the last twelve months the share price has lost 89.7%, trading between 1.49 and 18.89.
Tweenvest scores Cerenome, Inc. across four factors: quality 34/100, value 45/100. Its strongest factor is value.
CNSY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.45M
- Revenue (TTM)
- $4.20M
- P/E
- —
- EPS
- -4.37
- Dividend yield
- —
- Beta (5Y)
- 1.47
- 52-week high
- $18.89
- 52-week low
- $1.49
- Avg volume (3M)
- —
- Shares outstanding
- 7.59M
- Employees
- 28
- Next earnings
- —
About Cerenome, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
- ISIN
- US72941H8060
- Founded
- 1996
- Listed since
- Aug 3, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Genomtec S.A.WSE: GMT | $12.72M | zł2.90 | -5.70% |
| Algorae Pharmaceuticals LimitedASX: 1AI | $12.70M | AU$0.01 | +12.50% |
| America Great HealthOTCPK: AAGH | $12.69M | $0.00 | +100.00% |
| GT Biopharma, Inc.NasdaqCM: GTBP | $12.68M | $7.03 | +5.24% |
| Verici Dx plcAIM: VRCI | $12.45M | £0.00 | +4.44% |
| Clal Biotechnology Industries Ltd.TASE: CBI | $12.34M | ₪0.24 | +2.52% |
| Synlogic, Inc.OTCPK: SYBX | $12.25M | $1.00 | -9.09% |
| NextCell Pharma ABOM: NXTCL | $12.20M | Skr0.96 | -5.53% |
Figures last refreshed Oct 18, 2026.